A PHASE II SINGLE-ARM INTERVENTION TRIAL OF NELFINAVIR IN PATIENTS WITH GRADE 2/3 or 3 CERVICAL INTRAEPITHELIAL NEOPLASIA

Trial Profile

A PHASE II SINGLE-ARM INTERVENTION TRIAL OF NELFINAVIR IN PATIENTS WITH GRADE 2/3 or 3 CERVICAL INTRAEPITHELIAL NEOPLASIA

Recruiting
Phase of Trial: Phase II

Latest Information Update: 01 Mar 2017

At a glance

  • Drugs Nelfinavir (Primary)
  • Indications Cervical intraepithelial neoplasia
  • Focus Therapeutic Use
  • Most Recent Events

    • 22 Feb 2017 Planned End Date changed from 1 Dec 2016 to 1 Dec 2022.
    • 22 Feb 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2022.
    • 19 Jun 2015 Planned number of patients changed from 30 to 10 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top